Form 4: Apimeds Pharmaceuticals US, Inc. Director Acquires Shares
SEC Form 4 Filing
Christopher Kim, Director and Chairman/CMO of Apimeds Pharmaceuticals US, Inc., reports acquisition of 250,000 shares of common stock.
Summary
- Christopher Kim, a Director and the Chairman and CMO of Apimeds Pharmaceuticals US, Inc. (APUS), filed a Form 4.
- The report details a transaction on May 16, 2025, where Kim acquired 250,000 shares of common stock at $0 per share.
- Following this transaction, Kim directly owns 277,500 shares of Apimeds Pharmaceuticals US, Inc.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of share acquisition by a company insider.
Positives
- A director increasing their holdings in the company can be seen as a positive signal.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders.
Stakeholder Impact
- The acquisition of shares by a director could positively influence shareholder confidence.
Key Dates
| Date | Description |
|---|---|
| 05/16/2025 | Date of transaction where Christopher Kim acquired 250,000 shares. |
| 05/20/2025 | Date of signature on the Form 4 filing. |
Keywords
Form 4, Apimeds Pharmaceuticals US, Inc., Christopher Kim, Beneficial Ownership, Director, Share Acquisition, APUS
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.